Stock Data
$0.45 (5.15%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Ocular Therapeutix Inc is a pioneering biopharmaceutical firm dedicated to innovating eye care. Using its unique bioresorbable hydrogel technology, it develops treatments for various eye conditions. Its products include ReSure Sealant for cataract surgery recovery and DEXTENZA for post-surgical pain and inflammation, alongside treatments for allergic conjunctivitis. The company is also advancing research in therapies for age-related macular degeneration, glaucoma, and dry eye disease, with several products in clinical trials. Ocular Therapeutix collaborates with industry leaders like Regeneron Pharmaceuticals to enhance retinal disease treatments, marking its commitment to improving ocular health.
Ocular Therapeutix beat expectations on both lines, but the real catalyst is regulatory: AXPAXLI's NDA submission for wet AMD is locked for Q4 2026 via the faster 505(b)(2) pathway, potentially shaving 60 days off FDA review and setting up a 2027 launch when roughly 80% of retina specialists signal they'd adopt the product.
2 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
